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Wig-1 is a transcriptional target of the p53 tumor suppressor and encodes an mRNA stability-regulating protein. We show here
that Wig-1 knockdown causes a dramatic inhibition of N-Myc expression and triggers differentiation in neuroblastoma cells
carryingampliﬁedN-Myc.TransientWig-1knockdownsigniﬁcantlydelaysdevelopmentofN-Myc-driventumorsinmice.Wealso
show that N-Myc expression is induced upon moderate p53-activating stress, suggesting a role of the p53-Wig-1-N-Myc axis in
promotingcellcyclere-entryuponp53-inducedcellcyclearrestandDNArepair.Moreover,ourﬁndingsraisepossibilitiesforthe
improved treatment of poor prognosis neuroblastomas that carry ampliﬁed N-Myc.
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The p53 tumor suppressor is a transcription factor that
responds to cellular stress including DNA damage and
oncogene activation (reviewed in Vousden and Prives
1). p53
activation can result in a wide range of responses depending
on the stress agent and cellular context. The classical
outcomes of p53 activation are cell cycle arrest, senescence,
and apoptosis. Low levels of p53 caused by mild stress may
induce arrest and damage repair and maintain cell survival,
while high p53 levels in response to severe stress triggers
cell death by apoptosis.
1 Basal p53 levels also regulate
antioxidant activities and metabolism, promoting survival.
2
The importance of p53-mediated tumor suppression is
demonstrated by the high frequency of p53 mutations in
human tumors (reviewed in Soussi and Wiman
3 see also
www-p53.iarc.fr and free.p53.fr). Excessive p53 activity is
implicated in a number of neurological disorders character-
ized by untimely neuronal cell death.
1
Wig-1 (for wild-type p53-induced gene 1) is a direct p53
target gene identiﬁed in mouse,
4 rat,
5 and human cells.
5–7 It is
most strongly expressed in the nervous system, but is present
inall cell typeswithenrichmentinstemcellsascomparedwith
differentiated tissues.
8,9 Furthermore, Wig-1 is induced after
cellular stress in a p53-dependent manner.
8 Wig-1 is a zinc
ﬁnger protein that binds to double-stranded RNA,
10,11
and interacts with the RNA-binding proteins hnRNPA2/B1
and RNA Helicase A through RNA.
12 Wig-1 localizes mainly
to the nucleus but can shuttle between the nucleus and
the cytoplasm.
6,11,13,14 Wig-1 is highly conserved during
evolution from amoeba to man.
8 We have recently shown that
Wig-1canbindtoaU-richelementinthe30UTRofp53mRNA,
thereby stabilizing p53 mRNA by preventing its
de-adenylation.
13 The U-rich region in the p53 30UTR is a
subclass of the AU-rich elements (AREs) well known for their
role in regulating mRNA stability and/or translation efﬁciency.
AREs are generally found in mRNAs of genes whose
expressionmustbetightlycontrolled,suchasgenesencoding
proteins that regulate cell growth or response to external
factors.
15,16 ARE-interacting proteins are important nodes of
regulation as they can potentially control the levels of many
different mRNAs in the cell, and have been shown to have
important roles in cancer as well as development.
15,17 Thus
we hypothesized that Wig-1 regulates other ARE-containing
mRNAs in addition to that of p53. The mRNA of the N-Myc
oncogene contains both U-rich and AU-rich regions that are
bound by the nervous system-speciﬁc HuR family member
HuD.
18,19 N-Myc belongs to the Myc network of transcription
factors that can affect a wide variety of cellular processes
including cell growth, cell cycle entry, differentiation, and
apoptosis.
20 N-Myc is normally expressed mainly in nervous
tissues early during embryonic development, and is absent in
most adult tissues. However, ampliﬁcation of N-Myc occurs in
20–30% of neuroblastoma, a childhood tumor derived from
precursors or immature cells of the sympathetic nervous
system.
21 N-Myc ampliﬁcation is the most consistent marker
of poor prognosis and aggressive disease in neuroblas-
toma.
20,22 N-Myc knockdown by siRNA in neuroblastoma
cellscarryingN-Mycampliﬁcationcaninducedifferentiation,
23
and antisense strategies that target N-Myc inhibit mouse
neuroblastoma tumorigenesis in vivo.
24
Results
As the N-Myc mRNA is reported to be regulated through
AREs
18,19 we hypothesized that Wig-1 could affect N-Myc
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www.nature.com/cddisprotein and mRNA levels. We knocked down Wig-1 using two
different siRNA oligos in two neuroblastoma cell lines carrying
N-Myc ampliﬁcation, SK-N-BE(2) and Kelly (Figures 1a and
b),anddetectedasigniﬁcantreductioninN-Mycproteinlevels
in both cell lines with both siRNA oligos. The effect was more
pronounced using Wig-1 siRNA 1, which was also more
efﬁcientthan Wig-1siRNA 2inknockingdownWig-1. Wenext
testediftheeffectofWig-1onN-Myccouldbedetectedalsoat
the mRNA level, using the two different Wig-1 siRNA and
assessing N-Myc mRNA levels with the Quantigene assay.
Figure 1c demonstrates a reduction in N-Myc mRNA levels
compared with GAPDH mRNA levels by 45% and 36% using
siRNA oligo 1 and 2, respectively.
Next, we investigated if the AREs in the N-Myc 30UTR are
required for Wig-1-mediated regulation. The N-Myc 30UTR
contains a U-rich stretch and a general AU-rich region
containing two canonical AREs (Figure 2a, Supplementary
Figure S1). To examine the effect of Wig-1 on the N-Myc
30UTR, we used the psiCheck2 luciferase vector in which the
30UTR of interest is inserted downstream of renilla luciferase.
Using this system, we generated constructs containing either
full-length or partially deleted N-Myc 30UTRs, as well as a
negative control containing part of the p53 30UTR lacking the
U-rich region (and therefore not regulated by Wig-1
13)
(Figure 2b, Supplementary Figure S1). Wig-1 was knocked
Figure 1 N-Myc protein and mRNA levels are decreased upon Wig-1
knockdown. Wig-1 knockdown using two different siRNA oligos leads to decreased
N-Myc protein levels in SK-N-BE(2) (a) and Kelly (b) cells carrying N-Myc
ampliﬁcation.ArrowsindicatethetwomajorWig-1 proteinspecies,and*indicatesa
non-speciﬁcband.(c)Similarly,Wig-1knockdownleadstodecreasedN-MycmRNA
levels in SK-N-BE(2) cells, by 45% (P¼1.9 10
 5) with Wig-1 siRNA oligo 1 and
by 36% (P¼0.0001) by Wig-1 siRNA oligo 2 (n¼4), as assessed by the
Quantigeneassay.TheﬁgureshowsN-MycmRNAlevelsrelativetoGAPDHmRNA
levels. Error bars show S.D.
Figure 2 Wig-1regulatesN-MycmRNAbybindingtothe30UTR.TheN-Myc30UTRcontainsaU-richstretchandageneralAU-richregioncontainingtwocanonicalAREs
(a). To determine if Wig-1 regulates N-Myc through any of these regions, we generated the constructs in (b) linked to renilla luciferase and assessed renilla activity compared
with control luciferase activity. (c) Statistically signiﬁcant reduction after Wig-1 knockdown compared with control siRNA of relative renilla activities was observed with the
constructs containing the proximal ARE, that is, full-length N-Myc 30UTR (ﬂ) (P¼7.3 10
 5); D distal ARE (P¼0.006); and DU( P¼0.044), but not with the constructs
lackingthe proximal ARE (core and D both ARE, n.s. standsfor not signiﬁcant) (n¼4). To determine if Wig-1 binds to theN-Myc 30UTR – and in thatcase, identify theregion
required for binding – we used the constructs in panel (b) as templates for making biotinylated RNA probes that were mixed with cell lysates from HCT116 cells ectopically
expressingwild-typeWig-1.Biotinylatedprobeswerecapturedusingstreptavidinbeads,washed,andboundproteinswereanalyzedbywesternblotting.(e)Wig-1bindstothe
probes generated from constructs in panel (b) that contain the proximal ARE but not to those lacking it. PD¼pulldown. To investigate if the RNA binding capacity of Wig-1 is
required for the binding to N-Myc mRNA, we used luciferase constructs either without a 30UTR (‘control’) or with the 30UTR of N-Myc (‘N-Myc’) (d) as templates for making
biotinylatedRNA probes that were mixed with cell lysatesfrom HCT116cells ectopically expressing either wild-type Wig-1 (‘Wig-1’) or a zinc ﬁnger point mutant form of Wig-1
thatcannotbindtoRNA
10(‘mutWig-1’)andperformedthepulldownasabove.(f)Bindingofwild-typebutnotmutantWig-1tothe30UTRsofN-Myc,butnottothecontrolRNA.
Densitometry analysis using ImageJ showed 1.4 times more wt Wig-1 than mutant Wig-1 protein in the input, most likely reﬂecting decreased protein stability of the mutant
protein. However, 64.5 times more wt than mutant Wig-1 was bound to the N-Myc probe (f)
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Cell Death and Diseasedown in HCT116 cells that were subsequently transfected with
the luciferase constructs. Renilla luciferase activity was
assessed and normalized to ﬁreﬂy luciferase expressed from
the same vector. HCT116 rather than SK-N-BE(2) cells were
usedinthisexperimentbecauseofthelowplasmidtransfection
efﬁciency in the SK-N-BE(2) cells. Wig-1 expression and
efﬁcient knockdown in HCT116 cells are shown in
Supplementary Figure S2. We observed a decrease in renilla
luciferase activity relative to ﬁreﬂy activity of the construct
containing the full-length N-Myc 30UTR after Wig-1 knockdown
(Figure2c),demonstratingthatWig-1exertsitseffectonN-Myc
through the N-Myc 30UTR. Similar effects on relative renilla
luciferase activity were observed for the constructs containing
the proximal ARE, but not for the constructs lacking the
proximal ARE, indicating that Wig-1 regulates N-Myc mRNA
through this region. It is noteworthy that constructs lacking the
proximal ARE generated higher relative renilla luciferase
activity, suggesting that this region acts as a negative
regulatory element in the N-Myc 30UTR (Figure 2c).
As we previously showed that Wig-1 is an RNA-binding
protein that regulates p53 mRNA through direct binding to the
30UTR, we tested if Wig-1 can bind to the N-Myc 30UTR. We
generated probes by in vitro transcription of the constructs in
Figure 2b in the presence of biotinylated UTP. The biotiny-
lated RNA probes were used in pulldown assays with
ectopically expressed FLAG-tagged Wig-1 from HCT116 cell
lysates. Figure 2e shows that Wig-1 binds to the probes
containing the proximal AU-rich element of the N-Myc 30UTR,
butnot to the regionslacking it. Thus, Wig-1 bindsto the same
regionthatisrequiredfortheWig-1-mediatedregulationofthe
N-Myc 30UTR. To investigate if the RNA-binding properties of
Wig-1 are required for this interaction, we performed a biotin
pulldown assay using probes generated by in vitro transcrip-
tion of either the luciferase open reading frame (ORF) alone
(control) or the luciferase upstream of the N-Myc 30UTR
(Figure 2d). Figure 2f shows that Wig-1 binds to the N-Myc
30UTR probe but not to the control probe, while a zinc ﬁnger
point mutant form of Wig-1 which cannot bind to RNA
10,11 is
unable to bind to any of the biotinylated probes. Thus, we
conclude that Wig-1 binds to and exerts its effect through the
proximal AU-rich element in the N-Myc 30UTR.
N-Myc knockdown causes differentiation in SK-N-BE(2)
cells carrying ampliﬁed N-Myc.
23 As Wig-1 knockdown
signiﬁcantly decreases N-Myc levels in these cells, we asked
if Wig-1 knockdown has a corresponding effect on differentia-
tion. We transfected cells with control siRNA or siRNA
targeting Wig-1 or N-Myc for 4 days and recorded morpho-
logicalchangesbyphase-contrastimaging (Figure 3a).At this
time point, control transfected cells had grown to conﬂuence
but remained largely as solitary cells, while cells transfected
with N-Myc or Wig-1 siRNA ceased to grow and underwent
morphological changes with neurite protrusions that formed
network-like patterns between the cells. Moreover, we
observed upregulation of the differentiation marker Neuro-
peptide Y (NPY) at the mRNA level after Wig-1 and N-Myc
knockdown, conﬁrming that inhibition of N-Myc expression
resulted in differentiation (Figure 3b). We also found an
increased fraction of cells in the G1 phase of the cell cycle, in
agreement with the observed growth arrest and differentiation
(Figure 3c). Wig-1 siRNA 1 gave a more dramatic phenotype
than Wig-1 siRNA 2 in all experiments, consistent with its
higher efﬁciency in silencing Wig-1 and downregulating
N-Myc expression as shown by western blotting (Figure 1a).
To investigate if Wig-1 knockdown induces differentiation in
other neuroblastoma cell lines with ampliﬁed N-Myc, we
knocked down Wig-1 or N-Myc in the cell lines Kelly and
LAN-5, and recorded morphological changes as for SK-N-
BE(2). We noted differentiation-associated morphology in
both Kelly and LAN-5 (Supplementary Figure S3). In Kelly, we
also noted signiﬁcant cell death upon long-term N-Myc or
Wig-1 knockdown.
To conﬁrm that the observed effect of Wig-1 knockdown on
differentiation was indeed mediated through reduced N-Myc
levels, we overexpressed GFP-tagged N-Myc ORF (lacking
the 30UTR regulated by Wig-1), while Wig-1 was knocked
down by siRNA. We found that most GFP-positive cells had
an undifferentiated phenotype as opposed to their non-
transfected, differentiated neighboring cells (Figure 3d;
Supplementary Figure S4a). Furthermore, we knocked down
Wig-1 in SH-SY5Y neuroblastoma cells that do not carry
ampliﬁed N-Myc. We did not observe any signs of differentia-
tionuponWig-1knockdowninthesecells,whiledifferentiation
was readily induced by treatment with all-trans retinoic acid
(ATRA) as described
25 (Supplementary Figures S4b and c).
Thus, Wig-1 knockdown triggers differentiation in SK-N-BE(2)
cells carrying ampliﬁed N-Myc, and this effect is most likely
due to attenuated N-Myc expression.
We next investigated if Wig-1 knockdown had any impact
on tumor formation in vivo. We ﬁrst performed a colony
formation assay to determine the long-term effect of Wig-1
knockdown by transient siRNA transfection. SK-N-BE(2) cells
were transfected with siRNA against Wig-1 or control siRNA,
cultured for 8 days post transfection, and stained with Giemsa
staining. We noted a clear reduction in the number of colonies
after Wig-1 siRNA knockdown as compared with control
(Figure 4a). Having established this effect, we transfected
SK-N-BE(2) cells with either Wig-1 siRNA or control siRNA
and inoculated them subcutaneously in nude mice, using 10
mice for inoculation with siWig-1-transfected cells and 10
mice for inoculation with siControl-transfected cells. Efﬁcient
Wig-1 knockdown was conﬁrmed by western blotting in an
aliquot of the cells before inoculation (Supplementary Figure
S5a). We observed a signiﬁcantly longer time to tumor take
(as deﬁned by a tumor volume of 0.1ml or more) using Wig-1
siRNA-transfected cells as compared with control siRNA-
transfected cells. Average time to tumor take was 24 days in
the mice inoculated with Wig-1 siRNA-treated cells, as
compared with 19.5 days in the siControl group (Figure 4b
and c). We noted a similar difference using tumor volume of
0.2ml or more as deﬁnition of tumor take (Supplementary
Figure S5b). One out of ten mice in the siWig-1 xenograft
group remained tumor-free for the entire experiment, indicat-
ing that even transient loss of Wig-1 may be sufﬁcient to
eliminate the tumor-forming potential of the SK-N-BE(2) cells.
Once tumors were well established (tumor volume Z0.2ml),
we noted no further difference in growth rates between the
groups (Supplementary Figure S5c), which was expected
considering the transient Wig-1 knockdown. In general,
transient siRNA transfection does not cause a signiﬁcant
decrease in target protein expression beyond 96h post
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Cell Death and Diseasetransfection, meaning that once tumors were formed they
were expected to have reverted to baseline Wig-1 and N-Myc
expression levels. Indeed, analysis of several of the tumors
conﬁrmed that Wig-1 and N-Myc expression levels were
similar in established tumors from both siWig-1 and siControl
groups (Supplementary Figure S5d).
To further explore the biological signiﬁcance of a p53-Wig-
1-N-Myc axis, we hypothesized that N-Myc may be induced in
stress situations that will ultimately be resolved, in order to
facilitate cell cycle re-entry. To investigate if N-Myc is induced
after p53-activating stress, we treated wild-type p53-carrying
IMR-32 neuroblastoma cells with the chemotherapeutic drug
Irinotecan(Irn). Wedetectedincreased p53andWig-1protein
levels, as expected, and also observed a marked induction of
N-Myc expression (Figure 5).
Discussion
In this study we have identiﬁed Wig-1 as a novel and crucial
regulator of N-Myc mRNA. We show that Wig-1 binds and
regulates N-Myc mRNA through an ARE-containing region in
the N-Myc 30UTR, and that Wig-1 knockdown leads to
reduced N-Myc levels followed by differentiation in SK-N-
BE(2) cells with ampliﬁed N-Myc. We chose SK-N-BE(2) cells
for the differentiation experiments because they are known
to differentiate upon downregulation of N-Myc.
23 As
Figure 3 Wig-1 knockdown causes differentiation in SK-N-BE(2) cells carrying N-Myc ampliﬁcation. (a) Phase-contrast images of SK-N-BE(2) cells 4 days after siRNA
transfection at  20 magniﬁcation. Scale bars indicate 1000mm. Control transfected cells are conﬂuent and cells are growing as solitary cells with square-like morphology.
Wig-1 knockdown using two different siRNA oligos or N-Myc knockdown causes morphological changes associated with differentiation to varying degree. Cells become less
conﬂuent and neurite outgrowths appear. Numbers next to images indicate the average percentage of differentiated cells ± standard deviation of three independent
experiments, of at least 50 counted cells per experiment. To examine the effect of Wig-1 knockdown on the differentiation-associated marker NPY we transfected cells with
siRNAoligosagainstWig-1orN-Myc,harvestedcellsafter4days,isolatedRNAandperformedquantitativereal-timePCR.(b)IncreasedlevelsofNPY(P¼0.025withsiWig-
1_1 and 4.7 10
 6 for siWig-1_2) after Wig-1 knockdown (n¼3) compared with control PGK1 levels. Error bars show S.D. (b). To examine the effect or Wig-1 and N-Myc
knockdown on cell cycle distribution in SK-N-BE(2) cells, we performed FACS-PI cell cycle analysis 4 days after siRNA transfection. Wig-1 knockdown resulted in a 58%
(P¼0.0002; siWig-1_1) or 22% (P¼0.032; siWig-1_2) increase in the G1 fraction of cells, whereas N-Myc knockdown resulted in a 56% (P¼0.0001; siN-Myc) increase (c)
(n¼5). To conﬁrm that the effect of Wig-1 on differentiation is caused by downregulation of N-Myc, we cotransfected SK-N-BE(2) cells with Wig-1 siRNA and GFP-tagged
N-Myc ORF construct lacking the 30UTR (and therefore not regulated by Wig-1). Cells were ﬁxed and mounted for immunoﬂuorescence 5 days after transfection. (d) shows a
GFP-N-Myc ORF-expressing cell (cell borders marked in black) surrounded by non-transfected cells. The GFP-N-Myc-expressing cell remains undifferentiated whereas the
surrounding cells that do not express GFP-N-Myc show a differentiation-associated morphology. All images are at  63 magniﬁcation. Scale bars indicate 20mm. For more
examples, see Supplementary Figure 2a
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Cell Death and DiseaseARE-binding proteins such as Wig-1 generally have many
target mRNAs,
16 we cannot formally exclude that some other
putative Wig-1-regulated mRNA besides N-Myc may inﬂu-
ence differentiation after Wig-1 knockdown. However, N-Myc
is likely to be a critical Wig-1 target for induction of
differentiation as the SH-SY5Y neuroblastoma cells that do
not express N-Myc fail to differentiate upon Wig-1 knockdown
(Supplementary Figure S3b and c). In addition, the induction
of differentiation-associated morphology of Wig-1-depleted
SK-N-BE(2) cells can be prevented by ectopic expression of
N-Myc ORF (Figure 3d, Supplementary Figure S2a), indicat-
ing that N-Myc alone, in the absence of other putative Wig-1
targets, is sufﬁcient to maintain an undifferentiated
phenotype.
The fact that Wig-1 – target of the tumor suppressor
p53andstabilizerofp53mRNA
13–sustainsexpressionofthe
oncogene N-Myc is a striking example of the intricate
regulatory network that governs cellular life-and-death deci-
sions. While high levels of cellular stress in general are
associated with a p53-dependent apoptotic response, low or
moderate stress may induce p53-dependent cell cycle arrest
and DNA repair followed by cell cycle re-entry.
1 The marked
induction of N-Myc expression along with p53 and Wig-1
expression after treatment of wild-type p53-carrying IMR-32
neuroblastoma cells with the chemotherapeutic drug Irn
(Figure 5) suggests that upregulation of N-Myc via Wig-1
may have an important role in promoting the recovery and cell
survival after p53-induced cell cycle arrest in response to
stress. At the same time, Wig-1-mediated stabilization of p53
mRNA will lower the threshold for subsequent p53 activation
andthusincreasecellularalertnesstoDNAdamageandother
types of stress (Figure 6). This notion is supported by the fact
that the Wig-1 promoter has a perfect p53 response
element,
4,6 which is typically found in promoters of cell cycle
arrest-associated p53 target genes like p21.
26 Under physio-
logical conditions, it is likely that the regulation of N-Myc by
Wig-1 is most important in actively cycling cells relying on
N-Myc for their survival, such as neuronal and embryonic
stem cells. This hypothesis is consistent with the observed
enrichment of Wig-1 in stem cells and indications of a role for
Wig-1 in stem cell maintenance.
9,27 Indeed, we have noted
that Wig-1 expression is required for stem cell survival, as
Figure 4 Wig-1 knockdown delays tumor take in nude mice. Transient Wig-1
knockdown is sufﬁcient to cause long-term effects on SK-N-BE(2) cell growth. (a)A
colony formation assay with SK-N-BE(2) cells that were transfected either with
siRNA targeting Wig-1 or with control siRNA, incubated 8 days after transfection,
andﬁxedandstainedwith Giemsastaining.Theﬁgure showsrepresentative results
from one out of four independent experiments (a). Tumor take in the xenograft
model is delayed in SK-N-BE(2) cells pre-transfected with siRNA targeting Wig-1
compared with control siRNA. (b) Kaplan–Meier plots in which the median time to
tumor take deﬁned by a tumor volume of 0.1ml is 19.5 days in cells pre-transfected
with siControl and 24 days in cells pre-transfected with siWig-1 (P¼0.012).
(c) shows the same data represented in a scatter plot (P¼0.025)
Figure5 UpregulationofN-Mycuponp53andWig-1-inducingstress.Moderate
stress induced by the topoisomerase 2 inhibitor Irn induces p53 and Wig-1 at the
protein level, which leads to induction of N-Myc protein in the wild-type p53-carrying
neuroblastoma line IMR-32
Figure 6 The p53-Wig-1-N-Myc axis. Model for p53-dependent cell cycle arrest
and DNA repair induced by low to moderate cellular stress, followed by cell cycle
re-entry and resumed cell growth. Wig-1 may facilitate cell cycle progression and
survival post stress by sustaining levels of growth-promoting mRNAs such as
N-Myc, while simultaneously stabilizing p53 mRNA to facilitate subsequent p53
activation in case of remaining damage. It is also conceivable that low levels of p53
in unstressed cells can promote survival via induction of Wig-1. In case of severe
stress, cells will die from p53-mediated apoptosis
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Cell Death and Diseasedemonstrated by the early embryonic lethality of Wig-1
knockout mice (Vilborg et al., unpublished results). Thus we
propose that Wig-1 has a pro-survival role in cells by
sustaining N-Myc expression, and that the simultaneous
enhancement of p53 mRNA levels provides a safe-guard
mechanism for rapid induction of p53protein upon stress. The
details of such an intricate regulation remain to be elucidated.
It is interesting to note that the region of N-Myc 30UTR that is
required for Wig-1-mediated regulation consists of the
pentamer AUUUA with an AU-rich region surrounding it
(thisstudy),whiletheAREboundbyWig-1inthep5330UTRis
a stretch of continuous U’s.
13 Although there are no known
preferences for ARE-binding proteins with regard to different
AREs,
16 one could speculate that some modiﬁcation of the
Wig-1 protein might change its relative afﬁnities for the N-Myc
and the p53 AREs under different cellular conditions.
Finally,theobservationthattransientWig-1knockdowninthe
aggressivehumanneuroblastomaSK-N-BE(2)cellsissufﬁcient
to impair tumor development in nude mice, and, in 1 case out of
10, completely prevent tumor formation, raises interesting
therapeutic possibilities. It will be important to investigate the
effect of Wig-1 knockdown in vivo on already established
tumors. A Wig-1-based therapeutic strategy could either aim at
speciﬁcally inhibiting Wig-1 binding to N-Myc mRNA, or more
broadly targeting Wig-1 expression or RNA binding. The latter
approach is most likely to be useful in neuroblastoma with
mutant p53. p53 mutations occur in a subset of recurrent and
therapy-resistant neuroblastoma.
28 Mutant p53 has gain-of-
function activities that promote tumor growth.
29 We have found
that Wig-1 knockdown decreases levels of mutant p53 in the
SK-N-BE(2) cells (Supplementary Figure S6). Therefore,
therapeutic targeting of Wig-1 expression or RNA binding in
mutant p53-carrying tumors may have the added beneﬁt of
inhibiting mutant p53 gain-of-function activities. Thus, our
ﬁndings stronglysuggest that Wig-1knockdown, or interference
with Wig-1 RNA binding in general or N-Myc mRNA binding in
particular, would be fruitful strategies for treatment of aggres-
sive and recurrent neuroblastoma, which is a signiﬁcant cause
of death among young children.
Materials and Methods
Cell culture, transfection and colony formation assay. For details
on p53 and N-Myc status of neuroblastoma cell lines used in this study,
see Supplementary Table S1. Cells were grown in IMDM (HyClone, Logan, UT,
USA) with 1% glutamine (Sigma Aldrich, St. Louis, MO, USA), 10% FBS
(HyClone) and 50mg/ml Plasmocin (InVivoGen, San Diego, CA, USA). siRNA
transfections were performed in media without antibiotics using HiPerFect
(Qiagen, Hilden, Germany) according to the manufacturer’s protocol using the
following siRNA: wig1_1 wig1_2 N-Myc_5 and all stars negative control (all from
Qiagen), at a concentration of 10nM (for Quantigene assays, luciferase assays,
mouse xenograft experiments and three out of six of the differentiation
experiments in Kelly cells) or 20nM (for western blotting, differentiation assays,
and colony formation assays). For differentiation assays in SH-SY5Y cells
harvested 5 days after transfection, and LAN-5 and Kelly cells harvested 6 days
after transfection, cells were transfected with siRNA twice, the day following plating
and 2 days after the ﬁrst transfection. For differentiation rescue assays, SK-N-
BE(2) cells were plated in 6-well plates and transfected the following day with
pEGFP-C1-N-Myc, which was generated by subcloning the N-Myc ORF from
pLenti-III-Tet-h-MYCN-2A-dEGFP (Capital Biosciences, Rockville, MD, USA) into
the BglII site of the pEGFP-C1 vector by TOPO cloning using the pCR4 vector
(Invitrogen) according to the manufacturer’s protocol and using BglII restriction
site-containing primers: nmycF_bgl2 50-AGATCTATGCCGAGCTGCTCCAC-30,
and nmycR_bgl2 50-AGATCTAGCAAG-TCCGAGCGTGTT-30. After 6–8h the
cells were transfected with 40nM wig1_1 siRNA as above. The cells were cultured
for an additional 4 days and were then ﬁxed and mounted for immunoﬂuorescence
as described in Vilborg et al.
13 and photographed using a bright-ﬁeld microscope.
For the biotin pulldown assay, HCT116 cells were transfected using PEI according
to standard protocol with pCMVtag2bhWig-1 or pCMVtag2bhWig-1ZF1pm.
10 For
ATRA (Sigma Aldrich) treatment, SH-SY5Y cells were incubated with 10nM ATRA
for 5 days. For colony formation assays, SK-N-BE(2) cells were cultured 8 days
post transfection, ﬁxed and stained with Giemsa (Sigma Aldrich) according to the
manufacturer’s protocol. For mouse xenograft experiments, SK-N-BE(2) cells were
harvested 24h post transfection. Inoculations were performed as described below.
To ensure transfection efﬁciency, a few wells of each group were maintained for
an additional 24h, after which the cells were harvested for western blotting as
described below. For analysis of p53, N-Myc, and Wig-1 expression after stress,
IMR-32 cells were transfected with 40nM siControl 1 day post plating, treated with
0.4mM Irn, kept in culture for an additional 2 days, and then harvested for western
blotting as described below.
Western blotting. Cells were transfected as indicated, cultured for 48–72h,
harvested, and lysed in NP40 lysis buffer (100mM Tris pH 8.0, 150mM NaCl, 1%
NP40, 1% Protease Inhibitor Cocktail (Sigma Aldrich)). Tumor samples were
washed in PBS and homogenized for 1min using disposable pellet pestles
(Kontes, Vineland, NJ, USA) in 100 to 300ml of lysis buffer as above. Lysates
were cleared by centrifugation, and 30–50mg of protein were loaded on 10% SDS-
PAGE gels (Invitrogen) and run in 1 MOPS (Invitrogen). Gels were blotted to
nitrocellulose membranes using the iBlot (Invitrogen), blocked in 5% milk for 1h,
and incubated with the indicated antibodies. Wig-1 rabbit polyclonal 1:1000,
10 or
1:500 (GeneTex, Irvine, CA, USA), N-Myc: mouse monoclonal (NCM II 100)
1:200 Santa Cruz Biotechnology (Santa Cruz, CA, USA), GAPDH: rabbit
polyclonal (Fl-335) 1:2000 Santa Cruz Biotechnology, p53: mouse monoclonal
(DO-1) 1:1000 Pharmingen (San Diego, CA, USA), b-actin: mouse monoclonal
(Sigma Aldrich) 1:5000. Primary antibodies were detected using HRP-conjugated
secondary antibodies (GE Healthcare, Piscataway, NJ, USA) and Super Signal
West Femto Maximum Sensitivity Substrate (Thermo Scientiﬁc, Lafayette, CO,
USA) with a CCD camera (Fujiﬁlm, Tokyo, Japan).
Quantigene assays and quantitative real-time PCR. Cells were
transfected the day after plating, cultured an additional 48h, and then lysed and
analyzed with the Quantigene 2.0 assay (Panomics, Fremont, CA, USA, QS0008)
according to the manufacturer’s protocol using probes for N-Myc (SA-10008) and
GAPDH (SA-10001) (Panomics). For quantitative real-time PCR, total RNA was
extracted using Trizol (Invitrogen). Real-time PCR was carried out in an Applied
Biosystems 7500 real-time PCR machine using transcript-speciﬁc TaqMan Gene
Expression Assays (NPY: Hs00173470_m1, PGK1: Hs99999906_m1) (Applied
Biosystems, Foster City, CA, USA).
Luciferase assays and Biotin pulldown. For N-Myc 30UTR primer
sequences see Figure S1. psiCheck2 plasmid constructs were generated by PCR
subcloning into the TOPO10 cloning vector (Invitrogen) of the various N-Myc
30UTR constructs (see Supplementary Figure S1 for details) or, as control, the p53
30UTR lacking the U-rich region. The latter was cloned using p53 30UTR_F
(50-CAATGTCTCGAGACATTCTCCACTTCTTGTTCCC-30) and p53 30UTR_R
(50TAGTCAGCGGCCGCCACCCCTCAGACACACAGG-30) using pCS2þ -U
13
as template. The 30UTRs were then excised using Not1 and Xho1, and cloned into
the psiCheck2 vector (because of the presence of an Xho1 site in the p53 30UTR
the construct lacks the 346 most 30 nucleotides of the p53 30UTR). These
plasmids were then transfected using Lipofectamine 2000 (Invitrogen) according to
the manufacturer’s protocol in HCT116 cells that had been plated 24h earlier and
transfected with siRNA (siControl or siWig-1_2) 8 hours before DNA transfection.
Cells were cultured for an additional 20h and were then analyzed by Stop and Glo
luciferase kit (Promega, Madison, WI, USA) according to the manufacturer’s
protocol. Each experiment was performed in triplicate.
For biotin pulldown assays, either the psiCheck2 constructs from above were
used as templates, or pMirReport vector alone or with the N-Myc 30UTR
downstream of luciferase (kind gift from M. Corcoran) were used. Vectors were
linearized with Not1, column puriﬁed using columns from gel extraction kit (Qiagen)
according to the manufacturer’s protocol, and were then used as templates for
in vitro transcription using T7 or Sp6 polymerase (Roche, Indianapolis, IN, USA) in
the presence of biotin labeling mix containing biotinylated UTPs (Roche) according
to the manufacturer’s protocol. Approximately 5mg of probes were then incubated
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pCMVtag2bhWig-1orpCMVtag2bhWig-1ZF1pm,
10lysedandusedforthepulldown
as described in.
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Flow cytometry and propidium iodide staining. SK-N-BE(2) cells
were harvested 96h after transfection, resuspended in 3ml PBS and ﬁxed in 4ml
95% ethanol at 41C overnight. Cells were pelleted by centrifugation (500 g for
5min at 41C) resuspended in 100ml PI staining solution containing 0.05mg/ml PI
and 0.25mg/ml RNaseA in PBS and stained for 30min at 371C. An additional
300ml PBS was added to the sample, which was then analyzed by FACS using a
calibur ﬂow cytometer (Becton Dickinson, San Diego, CA, USA) using the FCS
express v3 software (De Novo Software, Los Angeles, CA, USA).
Animals and in vivo tumorigenicity. Female Sca:NMRI nu/nu mice (5–6
weeks old) (Charles River, Wilmington, MA, USA) were inoculated subcutaneously
in the right hind ﬂank with 20 10
6 of SK-N-BE(2) siWig-1 (n¼10) or SK-N-BE(2)
siControl (n¼10) cells under general anesthesia. Tumor growth was assessed
with digital calipers daily and up to 80 days after inoculation. Tumor volume was
calculated by the formula: (width)
2 length 0.44. A tumor was considered to be
established once it had reached a volume of 0.1ml (mean 0.13ml). The animals
were killed and the tumors were weighed 7 days after the tumor volume reached
0.2ml. The animals were housed at a maximum of ﬁve per cage in an enriched
environment and were provided with sterile food and water ad libitum. The animal
experiments were approved by the regional ethics committee for animal research
(N304/08) and were in accordance with the Animal Protection Law (SFS
1988:534), the Animal Protection Regulation (SFS 1988:539), and the
Regulation for the Swedish National Board for Laboratory Animals (SFS
1988:541).
Microscopy. For immunoﬂuorescence staining, SK-N-BE(2) cells were plated on
coverslips, transfected with siRNA as indicated above 24h past plating, cultured for
an additional 4 days, and then washed in PBS, ﬁxed in 4% paraformaldehyde, and
permeabilized with 0.5% Triton X-100. Slides were mounted using VECTASHIELD
HardSet Mounting Medium with DAPI, H-1500 (Vector Laboratories, Burlingame, CA,
USA), and examined under a Axioplan II Imaging (Carl Zeiss, Goettingen, Germany)
microscope equipped with a 63 /1.40 immersion objective (Plan-Apochromat, Carl
Zeiss) using an HBO-100 mercury lamp and ﬁlter sets for FITC and DAPI or HAL 100
light source for bright-ﬁeld pictures. Images were captured, processed, and analyzed
using an AxioCam MRm camera (Goettingen, Germany) and Axio Vision 4.8 software
(Carl Zeiss). For other bright-ﬁeld imaging, cells were grown in 6-well plates and
imaged using an Olympus (Center Valley, PA, USA) CK2 microscope equipped with
an LWD CD Arch  20 objective. Digital images were collected with a DeltaPix
(Maalov, Denmark) Invenio camera. All imaging was done at room temperature and
images were further processed with Photoshop CS5 (Adobe, San Jose, CA, USA).
Statistical analysis. Time to tumor take was compared using log-rank tests
for survival and comparison between animal groups was analyzed by the Mann–
Whitney U-test, all tests were two-sided. All other statistical tests were performed
using two-sided Student’s t-test.
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